Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Gamida Cell and the CRISPR gene-editing company Editas Medicine are joining forces to create a cancer therapy with natural killer (NK) cells. Gamida has a chemical method to expand the growth of NK cells, a kind of immune cell that can target tumors. A Phase I study of Gamida’s NK cell therapy for treating blood cancers is underway. Editas plans to engineer Gamida’s NK cells to make them better at killing tumors.
This article has been sent to the following recipient: